


Supplementary Figure S1. Impact of different biologic therapies on patients' preferences.



(a) Treatment experience with Adalimumab. Patients experienced with adalimumab were less interested in receiving tablets than those without this experience (PWU: -6.3, SD: 47.3 vs. PWU: 22.1, SD: 61.4, $p=0.017$). (b) Treatment experience with other biologics. The same preference pattern was found for patients experienced with any other biologic (i.e., certolizumab pegol ($n=1$), etanercept ($n=1$), golimumab ($n=1$), infliximab ($n=6$), secukinumab ($n=2$), vedolizumab ($n=1$), and biologics that could not be specified ($n=8$)), compared to patients naïve to these agents (PWU: -19.0, SD: 51.6 vs. PWU: 20.7, SD: 60.2, $p=0.014$). ** $p<0.01$. Bars: Means with standard deviations. RIS: Relative Importance Score; PWU: Part-worth utility; SD: Standard deviation.